Gilead Sciences, Inc. $GILD Stock Holdings Lifted by Ieq Capital LLC

Ieq Capital LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 375.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 160,503 shares of the biopharmaceutical company’s stock after buying an additional 126,764 shares during the period. Ieq Capital LLC’s holdings in Gilead Sciences were worth $23,923,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. BlackRock Inc. purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $15,393,785,000. Legal & General Group Plc acquired a new stake in Gilead Sciences in the second quarter valued at approximately $1,316,606,000. Deutsche Bank AG acquired a new stake in Gilead Sciences in the second quarter valued at approximately $918,387,000. Jupiter Topco LLC purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $398,905,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $166.53 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The business has a 50 day moving average price of $156.80 and a two-hundred day moving average price of $142.34. The firm has a market cap of $206.55 billion, a PE ratio of -52.70 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same period in the prior year, the company posted $2.47 EPS. Gilead Sciences’s quarterly revenue was up 6.8% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.97 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. Gilead Sciences’s payout ratio is presently -103.80%.

Insider Activity at Gilead Sciences

In other news, EVP Keeley Cain Wettan sold 3,399 shares of the company’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the sale, the executive vice president owned 5,360 shares in the company, valued at approximately $879,629.60. This represents a 38.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 9,810 shares of the company’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $175.17, for a total transaction of $1,718,417.70. Following the completion of the sale, the chief executive officer owned 551,683 shares in the company, valued at approximately $96,638,311.11. This trade represents a 1.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 237,709 shares of company stock worth $39,799,137 over the last quarter. Company insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on GILD. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. TD Cowen set a $175.00 price target on shares of Gilead Sciences in a report on Wednesday. Citigroup raised their price target on shares of Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a report on Friday, October 30th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $175.00 price target on shares of Gilead Sciences in a research note on Monday, November 2nd. Finally, Jefferies Financial Group set a $196.00 price objective on shares of Gilead Sciences in a report on Wednesday, November 4th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $171.63.

View Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Further Reading

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.